Skip to main content
. Author manuscript; available in PMC: 2020 Nov 16.
Published in final edited form as: Cancer Sci. 2011 May 9;102(7):1366–1373. doi: 10.1111/j.1349-7006.2011.01931.x

Table 4.

Blood biochemistry of each treatment group in vivo on day 29 (n = 7)

Control (PBS) SeV/ΔF/GFP SeV/ΔF/FIR P-value* P-value**
T-Bil (mg/dL) 0.067 ± 0.023 0.041 ± 0.020 0.076 ± 0.040 0.043 0.064
AST (IU/L) 141.7 ± 53.9 112.1 ± 46.2 181.0 ± 238.3 0.292 0.467
ALT (IU/L) 70.0 ± 43.9 71.3 ± 31.7 90.6 ± 131.1 0.951 0.712
LDH (IU/L) 2676.9 ± 1265.4 1712.1 ± 463.8 2286.4 ± 1319.1 0.083 0.299
BUN (mg/dL) 22.40 ± 3.49 21.94 ± 2.30 21.70 ± 3.32 0.778 0.876
Cr (mg/dL) 0.170 ± 0.019 0.123 ± 0.026 0.167 ± 0.062 0.002 0.11

Each value represents the median ± SD.

*

SeV/ΔF/GFP (1 × 108 CIU/body) compared with the control.

**

SeV/ΔF/FIR (1 × 108 CIU/body) compared with SeV/ΔF/GFP. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; LDH, lactate dehydrogenase; CIU, cell-infectious units; SeV/ΔF/FIR, fusion gene deleted non-transmissible Sendai virus vector encoding FUSE-binding protein-interacting repressor; SeV/ΔF/GFP, fusion gene deleted non-transmissible Sendai virus vector encoding green fluorescent protein; T-Bil, total bilirubin.